Therapeutics News and Research

RSS

Scientists discover four new genetic variants in humans linked with NAFLD

Five genetic variants in humans - four new - associate with Nonalcoholic Fatty Liver Disease, according to a study published March 10 in PLoS Genetics.

10 Mar 2011

Pepscan signs Research and License Agreement with Crucell to devlop novel vaccines

Pepscan Therapeutics, the Dutch biotechnology firm focusing on protein mimicry technology, today announces that it has signed a Research and License Agreement with Crucell Holland B.V. the Dutch developer of vaccines and antibodies.

10 Mar 2011

CTI announces final pixantrone clinical trial design for treatment of DLBCL

Cell Therapeutics, Inc. today announced the final clinical trial design of a randomized pivotal trial of pixantrone for the treatment of diffuse large B-cell lymphoma following discussions with the U.S. Food and Drug Administration's Division of Hematologic Products.

10 Mar 2011

Experimental drug effectively shuts off MCL1 gene and induces apoptosis

Predictive Biomarker Sciences (PBS-Bio) has uncovered how the experimental drug UNBS1450, produced by Unibioscreen, kills cancer cells.

10 Mar 2011

CRT, ICR sign deal with ZoBio to discover and develop cancer drugs

Cancer Research Technology and The Institute of Cancer Research have signed a deal with Dutch drug discovery company, ZoBio BV, to discover and develop drugs to block a DNA repair target which may play a role in cancer cell survival.

10 Mar 2011

FDA informs additional delay of ARYx's request for naronapride SPA

ARYx Therapeutics, Inc. today announced that the US Food and Drug Administration has informed the Company of an additional delay in providing needed guidance on the Phase 3 development of ARYx's product candidate for the treatment of various gastrointestinal disorders, naronapride. In this latest communication with ARYx, the FDA suggests a response will not be forthcoming until July 2011 at the earliest.

10 Mar 2011

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

Stemline Therapeutics, Inc. today announced that SL-401, the Company's lead compound, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).

10 Mar 2011

Israel grants patent to Kamada's Transferrin for use in Pharmaceutical Compositions

Kamada, a biopharmaceutical company developing, manufacturing and marketing specialty life-saving therapeutics, announced today it has received an Israeli Patent for its Ultrapure Transferrin to be used in Pharmaceutical Compositions.

10 Mar 2011

TARIS commences LiRIS Phase 1B clinical study in interstitial cystitis

TARIS Biomedical, a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases with high unmet medical need, announced that it has initiated a Phase 1B clinical study in patients with interstitial cystitis (IC). The study will evaluate the safety and tolerability of TARIS' innovative product candidate LiRIS® in patients suffering from moderate-to-severe IC.

10 Mar 2011

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

Cardium Therapeutics today announced the publication of positive findings from the Company's Matrix Phase 2b clinical study.

9 Mar 2011

NCCN, SNM enter cancer imaging research collaboration

The National Comprehensive Cancer Network- (NCCN-), and the Society of Nuclear Medicine (SNM) are pleased to announce a collaboration to advance research for cancer imaging and therapies. Specifically, NCCN will work with SNM to qualify imaging sites for upcoming research projects utilizing molecular imaging in clinical trials.

9 Mar 2011

Also in global health news: Rights abuses in Myanmar; Indian malnutrition; Mali Global Fund grant; shift in USAID's programs in Afghanistan; Gates Foundation grant for vaccines

Human Rights Abuses Impacting Health Situation In Parts Of Myanmar, Study Says.

9 Mar 2011

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

Amicus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND). AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.

9 Mar 2011

GTHP provides update on FDA PMA review for LightTouch non-invasive cervical cancer test

Guided Therapeutics, Inc., today provided an update on the U.S. Food and Drug Administration review process for its premarket approval application for the LightTouch non-invasive test for the early detection of cervical pre-cancer.

8 Mar 2011

IRB approves Guided Therapeutics light-based Barrett's Esophagus detection technology for human trial

Guided Therapeutics, Inc., developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it has received Institutional Review Board approval to begin testing its light-based detection technology in humans for Barrett's Esophagus, a precursor for esophageal cancer.

8 Mar 2011

hUCBs and MenSCs transplant may offer future therapeutic benefit for AD, stroke, ALS

Transplanting stem cells derived from umbilical cord blood cells and menstrual blood cells may offer future therapeutic benefit for those suffering from stroke, Alzheimer's disease, and amyotrophic lateral sclerosis, says a team of neuroscience researchers from the University of South Florida's Department of Neurosurgery and Brain Repair and collaborators from three private-sector research groups, Saneron CCEL Therapeutics, Inc., Tampa, FL, Cryo-Cell International, Inc., Oldsmar, FL, and Cryopraxis, Cell Praxis, BioRio, Rio de Janeiro, Brazil.

8 Mar 2011

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics.

7 Mar 2011

Duchenne Parent Project awards grant to AMT for DMD gene therapy

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the Duchenne Parent Project, based in the Netherlands, has awarded AMT a grant of EUR 145,000 to support the development of AMT-080, AMT's gene therapy for Duchenne Muscular Dystrophy.

7 Mar 2011

NCRM, CSCRM to become national force in regenerative medicine

In a move to streamline and accelerate the research and development of new stem cell and regenerative medicine technologies, the National Center for Regenerative Medicine and the Center for Stem Cell and Regenerative Medicine at Case Western Reserve University have been rolled into a single entity housed within the university's School of Medicine.

5 Mar 2011

CDI announces publication of footprint-free iPSCs production method in PLoS ONE journal

Cellular Dynamics International, the world's largest producer of human tissue cells for drug discovery and safety testing, today announced the publication of research demonstrating an efficient and scalable method of creating DNA integration-free, or footprint-free, induced pluripotent stem cells under a feeder-free condition using chemically defined media.

5 Mar 2011

Therapeutics News and Research

Scientists discover four new genetic variants in humans linked with NAFLD

Pepscan signs Research and License Agreement with Crucell to devlop novel vaccines

CTI announces final pixantrone clinical trial design for treatment of DLBCL

Experimental drug effectively shuts off MCL1 gene and induces apoptosis

CRT, ICR sign deal with ZoBio to discover and develop cancer drugs

FDA informs additional delay of ARYx's request for naronapride SPA

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

Israel grants patent to Kamada's Transferrin for use in Pharmaceutical Compositions

TARIS commences LiRIS Phase 1B clinical study in interstitial cystitis

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

NCCN, SNM enter cancer imaging research collaboration

Also in global health news: Rights abuses in Myanmar; Indian malnutrition; Mali Global Fund grant; shift in USAID's programs in Afghanistan; Gates Foundation grant for vaccines

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

GTHP provides update on FDA PMA review for LightTouch non-invasive cervical cancer test

IRB approves Guided Therapeutics light-based Barrett's Esophagus detection technology for human trial

hUCBs and MenSCs transplant may offer future therapeutic benefit for AD, stroke, ALS

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

Duchenne Parent Project awards grant to AMT for DMD gene therapy

NCRM, CSCRM to become national force in regenerative medicine

CDI announces publication of footprint-free iPSCs production method in PLoS ONE journal

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News